
Oncotarget
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Latest episodes

Sep 29, 2022 • 3min
Press Release: HIV/HPV-Related Metastatic Colorectal Cancer Response to Nivolumab
Exploring challenges in predicting Nivolumab response in an HIV-positive anal cancer patient with MSI, emphasizing molecular analysis for tailored treatment decisions.

Sep 28, 2022 • 7min
How High Altitudes Influence HIF-1, Gastric Cancer & Patient Survival
High altitudes influence various physiological processes like HIF-1 expression and vitamin D levels, impacting diseases like gastric cancer. GA incidence is higher at high altitudes due to hypoxia-induced HIF-1 activation. Understanding the role of HIF-1 in GA pathogenesis and prognosis is crucial for high-altitude populations.

Sep 26, 2022 • 6min
Trending With Impact: Protein-Based Risk Model Predicts Esophageal Cancer Recurrence
Exploring the protein-based risk model for esophageal cancer recurrence, researchers identify biomarkers to improve treatment outcomes. Four prognostic molecular signatures show promise in predicting disease recurrence and stratifying patients based on risk levels.

Sep 20, 2022 • 4min
Press Release: Targeting RCC w/Poly ADP-ribose Polymerase Inhibitors, Low-dose Alkylating Chemo
New research paper explores targeting Krebs-cycle-deficient renal cell carcinoma with PARP inhibitors and low-dose alkylating chemo. Loss-of-function mutations in FH and SDH genes induce cancer syndromes. Fumarate and succinate inhibit DNA repair pathway, leading to accumulation of DNA double-strand breaks. Researchers develop murine models demonstrating alterations in transcriptomic and methylation profile.

Sep 19, 2022 • 9min
Behind the Study: Inhibition of Resistant Triple-negative Breast Cancer Cells
Dr. Balraj Singh, a researcher from The University of Texas MD Anderson Cancer Center, discusses inhibiting resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine. They explore the efficacy of these drugs and their potential to overcome chemotherapy resistance. The podcast also delves into the use of 6MP in enhancing immune checkpoint blockage for combating autoimmunity and cancer cells.

Sep 15, 2022 • 4min
Press Release: An ABC Transporter as a Potential Target Against SHH-Medulloblastoma
Researchers from St. Jude Children’s Research Hospital discuss the challenges of treating SHH-Medulloblastoma in young children through standard methods such as radiation therapy and SMO inhibitors. They highlight the need for novel therapeutic approaches and explore the potential of an ABC transporter as a new target for treatment.

Sep 12, 2022 • 8min
Behind the Study: Targeting Lipid Metabolism in Treatment of Ovarian Cancer
Researchers Dr. Glenn Simmons Jr. and Dr. Stefani Thomas discuss targeting lipid metabolism in ovarian cancer treatment. They highlight the role of unsaturated fatty acids in cancer cell growth, chemotherapy resistance, and immune response evasion. The podcast explores challenges in current therapies and the use of mass spectrometry to identify potential targets for more effective treatments.

Sep 8, 2022 • 5min
Press Release: Imaging With Polypeptide Fusion Protein Targets Bladder Cancer
Discover the development of a targeted imaging probe for detecting bladder cancer using polypeptide fusion proteins. Learn about the high sensitivity and selectivity of a NIR probe in labeling tumor tissue, showcasing potential for clinical translation and patient imaging.

Sep 1, 2022 • 7min
Immunotherapy Response Predicted By Machine Learning & Gut Microbiomes
Exploring how machine learning is used to predict immunotherapy response with a focus on gut microbiomes. Studying the impact of gut microbiomes on the immune system and their potential as a biomarker. Analyzing the predictive potential of gut microbiomes in immunotherapy response and the significance of machine learning in understanding microbiome-immunotherapy interactions.

Aug 24, 2022 • 7min
Epigenetics and Immunotherapy Combined Fights Rare Lymphoma
Exploring the synergistic effects of epigenetic and immunotherapy treatments in managing aggressive blastic mantle cell lymphoma, a challenging subtype of non-Hodgkin’s lymphoma, with high recurrence rates and poor treatment outcomes. Researchers discuss potential breakthroughs in offering improved survival rates and long-term remissions through a combination of treatment modalities, paving the way for future research on predictive biomarkers.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.